Sesen Bio — Merger or Acquisition (December 2022)
24 slides from Sesen Bio's merger presentation, Dec 12, 2022
Slide 1: Harnessing the Power of Engineered Macrophages
HA RNESSING THE POWER OF ENGINEERED MACROPHAGES Carisma Therapeutics December 2022
Slide 2: Cautionary Note Regarding Forward-Looking Statements
212/8/2022 Cautionary Note Regarding Forward-Looking Statements Regarding Carisma Statements in this presentation regarding Carisma about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statem
Slide 3: Important Additional Information
3 Important Additional Information In connection with the proposed transaction between Carisma Therapeutics and Sesen Bio, Sesen Bio filed with the SEC a registration statement on Form S-4 on October 14, 2022 and Amendment No. 1 to the Form S-4 on November 21, 2022 (as amended, the Form S-4). The Fo
Slide 4: Carisma is Positioned for Success
4 • Cutting edge research and bioengineering: o Proprietary platform for macrophage targeted therapies o Autologous/ allogeneic/ in-vivo modalities o Broad potential therapeutic applications, in oncology & beyond • Strong patent position covering all CAR-M therapies • Early clinical data for lead pr
Slide 5: Macrophages: The Ultimate Multitasker
5 Macrophages can: • Traffic to tumors/inflammation • Phagocytose • Initiate immune response • Present antigen to T-cells • Resolve fibrosis • Induce tissue regeneration • Resolve immune response Macrophages: The Ultimate Multitasker liver lung CNS wound infection tumor TAM M1 macrophage M2 macropha
Slide 6: CAR-M Mechanism of Action: Multi-Pronged Attack on Cancer
6 CAR-M Mechanism of Action: Multi-Pronged Attack on Cancer Carisma’s technology has the potential to address the key challenges involved in treating solid tumors TRAFFICKING AND PHAGOCYTOSIS IMMUNE ACTIVATION ANTIGEN PRESENTATION Target cell 1st time only CAR-M The activated T-cell recognizes tumor
Slide 7: Carisma's Broad Myeloid Cell Engineering Platform
7 Carisma’s Broad Myeloid Cell Engineering Platform Proprietary technology, leading macrophage engineering know-how, and strong IP portfolio ensure leadership position Monocyte & Macrophage Engineering Capabilities: • Proprietary platforms for durable macrophage engineering with Ad5f35 or Vpx-LV vir
Slide 8: Strong Patent Position
8 Strong Patent Position Broad Coverage for Monocyte and Macrophage Targeted Therapies • Worldwide patent coverage with issued and pending applications in major markets • Multiple issued US patents covering CAR-M composition of matter • Broad patent portfolio covering: o Viral and non-viral methods
Slide 9: Carisma's Strategic Approach to Platform Expansion
9 Carisma’s Strategic Approach to Platform Expansion Initial focus on ex-vivo autologous approach expected to drive expansion into higher risk/reward modalities In-Vivo Delivery Oncology • Solid Tumors • Heme Malignancy Autologous Allogeneic Non-Oncology • Liver Fibrosis • Neurodegeneration • Autoim
Slide 10: Moderna Partnership Validates Approach
10 Moderna Partnership Validates Approach and Provides Significant Potential Value Inflection Points Promising data emerging with rapid execution on lead programs • Multiple development programs initiated, with goal of adding 2-3 new programs/year • LNP delivery demonstrating high specificity to mye
Slide 11: Platform Enhancements Drive First-in-Class Pipeline
11 Platform Enhancements Drive First-in-Class Pipeline Multiple value inflection points with significant partner support/funding IND = Investigational new drug * Phase 1 study is currently active and ongoing O nc ol og y Au to lo go us m RN A/ L NP No n- O nc ol og y Al lo ge ne ic (IS PC ) Product
Slide 12: CT-0508 Study 101 Interim Data Supports CAR-M Hypothesis
F E A S I B I L I T Y • CT-0508 was successfully manufactured from autologous mobilized monocytes • Patient product demonstrated high CAR expression, purity, viability, M1 polarization and confirmed functionality • No lymphodepletion 12 CT-0508 Study 101 Interim Data Supports CAR-M Hypothesis M E C
Slide 13: CT-0508 Treatment Led to Increased Myeloid Activation in TME
13 CT-0508 Treatment Led to Increased Myeloid Activation in TME A. Increased fraction of M1 macrophages in TME Figure A. N = 3/3 pts with paired biopsy scRNA SEQ data. Figure B, right. N =6/6 pts with paired biopsy bulk RNA SEQ data. Figure C. N = 6/6 pts with paired biopsy bulk RNA SEQ data. CS F3
Slide 14: CT-0508 Shown to Induce Adaptive Anti-Tumor Immunity
14 CT-0508 Shown to Induce Adaptive Anti-Tumor Immunity Summary: CT-0508 treatment led to increased effector T cell infiltration of the TME (Figure A). T cell clonality increased within the TME (Figure B, left). Newly emergent, previously undetectable T cell clones accumulated within the TME over ti
Slide 15: CAR-M Platform Development Strategy
N e x t G e n C o n s t r u c t s Enhance CAR-M killing, cytokine release, & T cell priming • CAR modification (hinge & co-stimulation) + additional payloads C A R - M + P D 1 B l o c k a d e Overcome late-stage patients’ T cell exhaustion • Phase I/II CT-0508 + Pembrolizumab study expected to start
Slide 16: CT-0508 Potential to Reverse Immune Checkpoint Blockade Resistance
16 CT-0508 Has Potential to Reverse Immune Checkpoint Blockade Resistance and Demonstrates Robust Synergy* 0 60 120 0 50 100 Days Su rv iv al p ro ba bi lit y (% ) CTRL CAR-M CAR-M + aPD-1 aPD-1 ✱✱✱✱ ✱ CT-0508 + pembrolizumab Study planned for 2H 2022 1 Synergistic anti-tumor activity Profound TME m
Slide 17: Carisma's CAR Monocyte Platform
17 Carisma’s CAR Monocyte Platform Rapid manufacture & durable persistence 2 Rapid Manufacturing Process Key Characteristics* • Improved cell dose and dosing flexibility • Improved trafficking • Improved persistence • Improved killing • Improved cytokine release • Improved potential for antigen pres
Slide 18: Next Gen CAR-M Discovery
18 Next Gen CAR-M Discovery Potential to increase potency & functionality 3 Antibody Phagocytic Receptor CTX-001 Innate Immune Activating Receptor* Phagocytosis Second Signal * Example: CD40, TLR2, TLR4, MyD88, Dectin-1, etc. Low “Stress Test” E:T Ratio: Adding MYD88/CD40 significantly increases ant
Slide 19: Off-the-Shelf iPSC Derived Myeloid Cells
19 Off-the-Shelf iPSC Derived Myeloid Cells Expandable, allogeneic, and potentially broadly applicable 4 Tumor Alone iPSC Macrophage iPSC CAR-M Tu m or B ur de n Time (hours) iCAR-M anti-tumor function in-vitro Production of iCAR-M >1,000x expansion iP SC M ac ro ph ag e GMP = Good manufacturing pra
Slide 20: Directly Reprogramming Myeloid Cells In Vivo with mRNA/LNP
20 Directly Reprogramming Myeloid Cells In Vivo with mRNA/LNP • Myeloid tropic LNP have demonstrated specificity and efficient transfection in vivo • LNP have proven safety profile in previous clinical studies; repeat dosing well tolerated • High CAR expression and function in vitro. • In vivo studi
Slide 21: Platform Enables Potential Non-Oncology Applications
21 Platform Enables Potential Non-Oncology Applications Significant opportunity for strategic partnerships 1 Anti-inflammatory, anti-fibrotic macrophages: • Modality: Auto/Allo Cell Therapy • Potential indication: Liver Fibrosis • Payload: Immunosuppressive cytokine + anti-fibrotic enzyme 2 In vivo
Slide 22: Strong Leadership Team and Advisors
22 Strong Leadership Team and Advisors Deep research, clinical and operational expertise in cell and gene therapy and oncology Board of Directors • Sanford Zweifach – Chairperson • Briggs Morrison – Independent Director • Margarita Chavez – AbbVie Ventures • Bjorn Odlander – HealthCap • Regina Hodit
Slide 23: Operating Plan and Corporate Milestones
23 Operating Plan and Corporate Milestones Capital efficient R&D program designed to reach significant value inflection points over next 18 months Complete expanded CT-0508 Phase I study • Cohort 2: Bolus dosing • IP Administration • Anti-PD1 combination Advance our engineered macrophage platform •
Slide 24: Corporate Summary
24 Corporate Summary Significant opportunity to become a breakthrough therapeutics company Proprietary engineered macrophage platform Emerging pipeline of oncology CAR-Ms Validating partnership and clinical data Experienced leadership team and advisors Multiple potential value catalysts over next 18